HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) All Versions of this Article: dc07-1745v1 31/2/363    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cubbon, R. M Articles by Hall, A. S Search for Related Content PubMed PubMed Citation Articles by Cubbon, R. M Articles by Hall, A. S Social Bookmarking                What's this?

Aspirin and mortality in patients with Diabetes Mellitus sustaining Acute Coronary Syndrome

¹Leeds Institute of Genetics, Health & Therapeutics, The LIGHT laboratories, The University of Leeds, Clarendon Way, Leeds; LS2 9JT, United Kingdom
²BHF Heart Research Centre, Jubilee Wing, Leeds General Infirmary, Great George Street, Leeds; LS1 3EX, United Kingdom
³Department of Clinical Biochemistry and Immunology, Leeds General Infirmary, Great George Street, Leeds; LS1 3EX, United Kingdom

m.t.kearney{at}leeds.ac.uk

ABSTRACT

Objective: Comparison of mortality reduction associated with secondary prevention in patients with and without diabetes mellitus (DM) after acute coronary syndrome (ACS).

Research design and methods: Cohort study involving 2499 patients with ACS recruited from 11 UK hospitals. Multivariable analysis comparing all cause mortality risk reduction associated with pharmacologic agents in patients with and without DM.

Results: Aspirin was not associated with significant mortality benefit in DM sufferers (95% CI 0.50-1.08); non-diabetic patients derived a 48% mortality reduction (p<0.001). The interaction between DM and aspirin use was statistically significant (p=0.037), indicating patients with DM experience less effective mortality reduction from aspirin use.

Conclusions: Aspirin, but not other secondary prevention agents, is associated with less effective mortality reduction in patients with DM and unstable coronary artery disease.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. B. Hirsch, S. E. Inzucchi, and M. S. Kirkman Standards of Medical Care in Diabetes--2008: Response to Dora, Kramer, and Canani Diabetes Care, May 1, 2008; 31(5): e45 - e45. [Full Text] [PDF]